Clinical Trial

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-05; most recent amendment 2026-03-19.
Status change: Not Yet Recruiting → Recruiting 2025-07-08
Trial Details
NCT Number NCT07009860
Lead Sponsor Altimmune, Inc.
Conditions Alcohol Liver Disease
Enrollment 100 participants
Start Date 2025-06-16
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-20